"Designing Growth Strategies is in our DNA"
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to an insufficient amount of red cells in the blood. The disease is characterized by the inability to produce red blood cells. Moreover, improper functioning of bone marrow also results in the lack of red blood cells in the blood, which in turn results in a decrease in platelet numbers. Some of the common types of orphan disease which results in acquired orphan blood disease are paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, acquired agranulocytosis, and polycythemia vera (PV). Rising prevalence of blood-related disorders, growing awareness among people about these disorders, and improved healthcare infrastructure are some of the factors that are expected to drive the market growth during the forecast period.
Key Market Driver -
Rising prevalence of blood-related disorders
Key Market Restraint -
Stringent regulatory policies
Rising prevalence of blood-related disorders, growing geriatric population, increasing awareness among people about healthcare, and government initiatives for increasing awareness regarding occurrences of blood-realted disorders are some of the major factors that are driving the market growth.
However, long duration of time required for the approval of orphan blood diseases drug and stringent governemnt regulations are some of the factors expected to restrain the growth of acquired orphan blood diseases therapeutics market during the forecast period.
By therapy, the market can be segmented into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others. By disease indication, the market can be segmented into acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. By distribution channel, the market can be segmented into hospital pharmacy, retail pharmacy, and others.
Geographically, the acquired orphan blood diseases therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The major companies in the global acquired orphan blood diseases therapeutics market report includes Amgen Inc., Shire plc, Alexion Pharmaceuticals, Celgene Corporation, Rigel Pharmaceuticals, Inc., Otsuka Pharmaceutical Pvt. Ltd., Novo Nordisk Inc. and other prominent players.
The global acquired orphan blood diseases therapeutics market is expected to be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to lead the global acquired orphan blood diseases therapeutics market due to an increasing prevalence of blood-related disorders and increasing research and development investment in the U.S. According to the Statista, about 18,000 patients had haemophilia and over 13,000 patients had von willebrand syndrome, as of 2018.
To gain extensive insights into the market, Request for Customization
Europe is likely to have substantial market growth throughout the forecast period owing to the rising prevalence of blood-related disorders. Asia Pacific and Latin America are expected to register a fast market growth during the forecast period due to the increasing awareness about the acquired orphan blood diseases and its treatment among the people. On the other hand, Middle East and Africa is projected to have comparatively less CAGR in the acquired orphan blood diseases therapeutics market in the upcoming years.
By Disease Indication
By Distribution Channel
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry